Jubilant Life joins hand with Inipharm Inc for over Rs 199 crore

Published On 2018-11-30 04:00 GMT   |   Update On 2018-11-30 04:00 GMT

NEW DELHI: Drug firm Jubilant Life Sciences on Thursday said its subsidiary Drug Discovery and Development Solutions Ltd (DDDSL) Singapore has entered into an agreement to acquire 10 per cent stake in Inipharm Inc USA for around USD 28.5 million (over Rs 199 crore).


The company's wholly-owned subsidiary has entered into a stock purchase agreement to acquire 534,194 shares of common stock of biotechnology firm Inipharm Inc USA, for a cash consideration of USD 534.20 per share, Jubilant Life Sciences said in a filing to BSE.


The indicative time period for completion of the acquisition is three months, it added.


Shares of Jubilant Life Sciences were trading at Rs 740.50 per scrip in the afternoon trade on the BSE, up 6.61 per cent from their previous close.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News